Establishing legal limits for driving under the influence of marijuana

Injury Epidemiology

Volumn 1, Issue 1, 2014, Pages 1-8

  Wong, Kristin ^a   Brady, Joanne E ^a,b   Li, Guohua ^a,b,c  

^a Columbia University ^*  (United States)

^b Columbia University Medical Center ^*  (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Cannabis; Drugged driving; Legal limit; Marijuana; Per se; Psychomotor impairment

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CANNABIS; COCAINE; TETRAHYDROCANNABINOL;

ALCOHOL CONSUMPTION; CANNABIS SMOKING; COGNITION; DRIVING ABILITY; EUROPE; HUMAN; LAW; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 84988973611     PISSN: None     EISSN: 21971714     Source Type: Journal    
DOI: 10.1186/s40621-014-0026-z     Document Type: Review

References (61)

1. Asbridge M: Driving after marijuana use: the changing face of "impaired" driving.JAMA Pediatr 2014,168(7):602–4. 10.1001/jamapediatrics.2014.83
2. Ashton CH: Pharmacology and effects of cannabis: a brief review.Br J Psychiatry. 2001, 178: 101–6. 10.1192/bjp.178.2.101
3. Avila EN. Minimum Levels of Controlled Substances or Their Metabolites in Blood to Establish Presence of Controlled Substance.Pennsylvania Bulletin. 2011; 41(18): 2295.
4. Barceloux DC: Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons, Hoboken, NJ; 2012.
5. Barry RA, Hiilamo H, Glantz SA: Waiting for the opportune moment: the tobacco industry and marijuana legalization.The Milbank Quarterly 2014,92(2):207–42. 10.1111/1468-0009.12055
6. Beck O: Exhaled breath for drugs of abuse testing - evaluation in criminal justice settings.Sci Justice 2014,54(1):57–60. 10.1016/j.scijus.2013.09.007
7. Bedard M, Dubois S, Weaver B: The impact of cannabis on driving.Can J Public Health 2007,98(1):6–11.
8. Bosker WM, Kuypers KP, Theunissen EL, Surinx A, Blankespoor RJ, Skopp G, Jeffery WK, Walls HC, van Leeuwen CJ, Ramaekers JG: Medicinal Delta(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests.Addiction 2012,107(10):1837–44. 10.1111/j.1360-0443.2012.03928.x
9. Brady JE, Li G: Prevalence of alcohol and other drugs in fatally injured drivers.Addiction 2013,108(1):104–14. 10.1111/j.1360-0443.2012.03993.x
10. Brady JE, Li G: Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999–2010.Am J Epidemiol 2014,179(6):692–9. 10.1093/aje/kwt327
11. Chu M, Gerostamoulos D, Beyer J, Rodda L, Boorman M, Drummer OH: The incidence of drugs of impairment in oral fluid from random roadside testing.Forensic Sci Int 2012,215(1–3):28–31. 10.1016/j.forsciint.2011.05.012
12. Davey J, Freeman J: Screening for drugs in oral fluid: drug driving and illicit drug use in a sample of Queensland motorists.Traffic Inj Prev 2009,10(3):231–6. 10.1080/15389580902826817
13. De Giovanni N, Fucci N: The current status of sweat testing for drugs of abuse: a review.Curr Med Chem 2013,20(4):545–61.
14. de la Torre R, Pichini S: Usefulness of sweat testing for the detection of cannabis smoke.Clin Chem 2004,50(11):1961–2. 10.1373/clinchem.2004.040758
15. Downey LA, King R, Papafotiou K, Swann P, Ogden E, Boorman M, Stough C: The effects of cannabis and alcohol on simulated driving: Influences of dose and experience.Accid Anal Prev. 2013, 50: 879–86. 10.1016/j.aap.2012.07.016
16. DuPont RL, Voas RB, Walsh JM, Shea C, Talpins SK, Neil MM: The need for drugged driving per se laws: a commentary.Traffic Inj Prev 2012,13(1):31–42. 10.1080/15389588.2011.632658
17. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Responding to drug driving in Europe. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal; 2009.
18. Gjerde H, Normann PT, Christophersen AS, Morland J: Prevalence of driving with blood drug concentrations above proposed new legal limits in Norway: estimations based on drug concentrations in oral fluid.Forensic Sci Int 2011,210(1–3):221–7. 10.1016/j.forsciint.2011.03.021
19. Gjerde H, Normann PT, Christophersen AS, Samuelsen SO, Morland J: Alcohol, psychoactive drugs and fatal road traffic accidents in Norway: a case–control study.Accid Anal Prev 2011,43(3):1197–203. 10.1016/j.aap.2010.12.034
20. Grotenhermen F, Leson G, Berghaus G, Drummer OH, Kruger HP, Longo M, Moskowitz H, Perrine B, Ramaekers JG, Smiley A, Tunbridge R: Developing limits for driving under cannabis.Addiction 2007,102(12):1910–7. 10.1111/j.1360-0443.2007.02009.x
21. Hall W, Degenhardt L: Adverse health effects of non-medical cannabis use.Lancet 2009,374(9698):1383–91. 10.1016/S0140-6736(09)61037-0
22. Hartman RL, Huestis MA: Cannabis effects on driving skills.Clin Chem 2013,59(3):478–92. 10.1373/clinchem.2012.194381
23. Himes SK, Scheidweiler KB, Beck O, Gorelick DA, Desrosiers NA, Huestis MA: Cannabinoids in exhaled breath following controlled administration of smoked cannabis.Clin Chem 2013,59(12):1780–9. 10.1373/clinchem.2013.207407
24. Huestis MA: Human Cannabinoid Pharmacokinetics.Chem Biodivers 2007,4(8):1770–804. 10.1002/cbdv.200790152
25. Huestis MA, Cone EJ: Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis.J Anal Toxicol 2004,28(6):394–9. 10.1093/jat/28.6.394
26. Huestis MA, Scheidweiler KB, Saito T, Fortner N, Abraham T, Gustafson RA, Smith ML: Excretion of Delta9-tetrahydrocannabinol in sweat.Forensic Sci Int 2008,174(2–3):173–7. 10.1016/j.forsciint.2007.04.002
27. Huestis MA, Verstraete AG, Kwong TC, Morland J, Vincent MJ, de la Torre R: Oral Fluid Testing: Promises and Pitfalls.Clin Chem 2011,57(6):805–10. 10.1373/clinchem.2010.152124
28. Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin HJ, Lancon C: Acute and long-term effects of cannabis use: a review.Curr Pharm Des 2014,20(25):4112–8. 10.2174/13816128113199990620
29. Kay GG, Logan BK: Drugged Driving Expert Panel Report: A Consensus Protocol for Assessing the Potential of Drugs to Impair Driving. National Highway Traffic Safety Administration, Washington, DC; 2011.
30. Kilmer B: Policy designs for cannabis legalization: starting with the eight Ps.Am J Drug Alcohol Abuse 2014,40(4):259–61. 10.3109/00952990.2014.894047
31. Lacey J, Brainard K, Snitow S: Drug Per Se Laws: A Review of Their Use in States. National Highway Traffic Safety Administration (NHTSA), Washington, D.C; 2010.
32. Lee D, Schroeder JR, Karschner EL, Goodwin RS, Hirvonen J, Gorelick DA, Huestis MA: Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment.Am J Addict 2014,23(3):234–42. 10.1111/j.1521-0391.2014.12088.x
33. Li G, Brady JE, Chen Q: Drug use and fatal motor vehicle crashes: a case–control study.Accid Anal Prev. 2013, 60: 205–10. 10.1016/j.aap.2013.09.001
34. Moskowitz H: Marihuana and driving.Accid Anal Prev 1985,17(4):323–45. 10.1016/0001-4575(85)90034-X
35. Nahas GG: The pharmacokinetics of THC in fat and brain: resulting functional responses to marihuana smoking.Hum Psychopharmacol 2001,16(3):247–55. 10.1002/hup.258
36. National Organization for the Reform of Marijuana Laws (NORML). Drugged Driving. Washington, D.C: 2014a. Accessed July 15 2014., [http://norml.org/legal/drugged-driving]
37. National Organization for the Reform of Marijuana Laws (NORML). Marijuana Drug Test Detection Times. Washington, D.C: 2014b. Accessed July 25 2014., [http://www.canorml.org/healthfacts/drugtestguide/drugtestdetection.html]
38. National Organization for the Reform of Marijuana Laws (NORML). States that Have Decriminalized. Washington, D.C: 2014c. Accessed July 20 2014., [http://norml.org/aboutmarijuana/item/states-that-have-decriminalized]
39. Office of National Drug Control Policy (ONDCP). 2010 National Drug Control Strategy. Office of National Drug Control Policy, Washington, DC; 2010.
40. Office of National Drug Control Policy (ONDCP). 2013 National Drug Control Stragey. Office of the National Drug Control Policy, Washington, DC; 2013.
41. Ramaekers JG, Berghaus G, van Laar M, Drummer OH: Dose related risk of motor vehicle crashes after cannabis use.Drug Alcohol Depend 2004,73(2):109–19. 10.1016/j.drugalcdep.2003.10.008
42. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G: Cognition and motor control as a function of Delta-9-THC concentration in serum and oral fluid: limits of impairment.Drug Alcohol Depend 2006,85(2):114–22. 10.1016/j.drugalcdep.2006.03.015
43. Reisfield GM, Goldberger BA, Gold MS, DuPont RL: The mirage of impairing drug concentration thresholds: a rationale for zero tolerance per se driving under the influence of drugs laws.J Anal Toxicol 2012,36(5):353–6. 10.1093/jat/bks037
44. Romano E, Pollini RA: Patterns of drug use in fatal crashes.Addiction 2013,108(8):1428–38. 10.1111/add.12180
45. Romano E, Voas RB: Drug and alcohol involvement in four types of fatal crashes.J Stud Alcohol Drugs 2011,72(4):567–76.
46. Salomonsen-Sautel S, Min SJ, Sakai JT, Thurstone C, Hopfer C: Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado.Drug Alcohol Depend. 2014, 140: 137–44. 10.1016/j.drugalcdep.2014.04.008
47. Samyn N, Verstraete A, Van Haeren C, Kintz P: Analysis of drugs of abuse in saliva.Forensic Sci Rev 1999, 11: 2–17.
48. Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA: Psychomotor performance, subjective and physiological effects and whole blood Delta(9)-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.J Anal Toxicol 2012,36(6):405–12. 10.1093/jat/bks044
49. Sewell RA, Poling J, Sofuoglu M: The effect of cannabis compared with alcohol on driving.Am J Addict 2009,18(3):185–93. 10.1080/10550490902786934
50. Sharma P, Murthy P, Bharath MM: Chemistry, metabolism, and toxicology of cannabis: clinical implications.Iran J Psychiatry 2012,7(4):149–56.
51. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. U.S. Department of Health and Human Services, Rockville, MD; 2013.
52. Svrakic DM, Lustman PJ, Mallya A, Lynn TA, Finney R, Svrakic NM: Legalization, decriminalization & medicinal use of cannabis: a scientific and public health perspective.Mo Med 2012,109(2):90–8.
53. Talpins SK, Hayes C: The Drug Evaluation and Classification (DEC) Program: Targeting Hardcore Impaired Drivers. American Prosecutors Research Institute, Alexandria, VA; 2004.
54. Verstraete AG: Detection Times of Drugs of Abuse in Blood, Urine, and Oral Fluid.Ther Drug Monit 2004,26(2):200–5. 10.1097/00007691-200404000-00020
55. Verstraete AG, Knoche A, Jantos R, Skopp G, Gjerde H, Vindenes V, Mørland J, Langel K, Lillsunde P: Per se limits - Methods of defining cut-off values for zero tolerance. DRUID Project, Bergisch Gladbach, Germany; 2011.
56. Vindenes V, Lund HM, Andresen W, Gjerde H, Ikdahl SE, Christophersen AS, Øiestad EL: Detection of drugs of abuse in simultaneously collected oral fluid, urine and blood from Norwegian drug drivers.Forensic Sci Int 2012,219(1–3):165–71. 10.1016/j.forsciint.2012.01.001
57. Walsh JM: A State-by-State Analysis of Laws Dealing With Driving Under the Influence of Drugs. National Highway Traffic Safety Administration (NHTSA), Washington, D.C; 2009.
58. Wash Rev Code § 46.61.502.
59. Whitehill JM, Rivara FP, Moreno MA: Marijuana-using drivers, alcohol-using drivers, and their passengers: prevalence and risk factors among underage college students.JAMA Pediatr 2014,168(7):618–24. 10.1001/jamapediatrics.2013.5300
60. Wilson FA, Stimpson JP, Pagan JA: Fatal crashes from drivers testing positive for drugs in the U.S., 1993–2010.Public Health Rep 2014,129(4):342–50.
61. Wolff K, Johnston A: Cannabis use: a perspective in relation to the proposed UK drug-driving legislation.Drug Test Anal 2014,6(1–2):143–54. 10.1002/dta.1588